Clinical Trial to Evaluate the Tolerance of TQB2210 Injection
NCT ID: NCT06929195
Last Updated: 2025-05-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
90 participants
INTERVENTIONAL
2025-05-16
2027-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Trial of the TQB2102 Injection in Patients With Advanced Cancers
NCT05735496
Clinical Trial of TQB2868 Injection in Subjects With Advanced Malignant Tumors
NCT05198505
Clinical Trial of TQB2922 for Injection in Patients With Advanced Cancers
NCT06188624
Clinical Trial of the TQB2930 Injection in Patients With Advanced Cancers
NCT05380882
Clinical Trial of TQB3002 in Patients With Advanced Cancers
NCT06662760
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TQB2210 Injection
Dose escalation experiment:
Intravenous infusion once of TQB2210 for injection every two weeks, 28 days as one treatment cycle.
(1.0 mg/kg, 3.0 mg/kg, 8.0 mg/kg, 16.0 mg/kg, 24.0 mg/kg)
Dose expansion experiment:
Chose one or two appropriate dose groups in the dose escalation experiment to amplify.
TQB2210 Injection
TQB2210 injection is a humanized monoclonal antibody against FGFR2b, which can bind to FGFR2b with high specificity. It inhibits tumor growth by blocking the signaling pathway mediated by fibroblast growth factor receptor. Its binding is concentration dependent.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TQB2210 Injection
TQB2210 injection is a humanized monoclonal antibody against FGFR2b, which can bind to FGFR2b with high specificity. It inhibits tumor growth by blocking the signaling pathway mediated by fibroblast growth factor receptor. Its binding is concentration dependent.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At least one tumour lesion that can be evaluated according to Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 in the dose-escalation phase and at least one measurable lesion in the dose-expansion phase.
* Good function of major organs.
* Patients with advanced malignant tumours confirmed by histology or cytology, disease progression or intolerance after adequate standard treatment, lack of standard treatment options.
* Can provide tumor tissue specimens collected fresh or sliced within 6 months (preserved in wax blocks collected within 3 years) for further detection for FGFR2b expression
* Fertile subjects should agree that contraception must be used during the study and for 6 months after the end of the study; Women of childbearing age had a negative serum pregnancy test within 7 days prior to study enrollment and had to be non-lactating subjects.
* Evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study.
Exclusion Criteria
* There are diseases that affect intravenous injection and venous blood collection
* Adverse reactions from previous treatments have not recovered to CTCAE v5.0 Grade 1
* Received major surgical treatment, significant traumatic injury within 4 weeks prior to the first dose of TQB2210, or exist long-term unhealed wounds or fractures
* Subjects who experience any bleeding or bleeding events ≥ CTCAE grade 3 within 4 weeks prior to the first dose of TQB2210
* An arterial/venous thrombotic event occurred within 6 months prior to to the first dose of TQB2210
* Patients with active viral hepatitis that is poorly controlled
* Active syphilis patients requiring treatment
* A history of active pulmonary tuberculosis, idiopathic pulmonary fibrosis, institutional pneumonia, drug-induced pneumonitis/radiation pneumonia requiring treatment or active pneumonia with obvious clinical symptoms, interstitial pneumonia requiring treatment
* Subjects with any severe and/or uncontrolled illnesses
* Individuals who are preparing for or have previously undergone allogeneic bone marrow transplantation or solid organ transplantation
* History of hepatic encephalopathy
* Suffering from significant cardiovascular disease
* Active or uncontrolled severe infections
* Patients with renal failure requiring hemodialysis or peritoneal dialysis;
* Corneal defects, corneal ulcers, keratitis or keratoconus, history of corneal transplantation, or other known corneal abnormalities that may increase the risk of developing corneal ulcers within 6 months prior to the first treatment or currently present
* History of retinal disease or retinal detachment, or increased risk of retinal detachment according to the opinion of an ophthalmologist
* Acute ophthalmic diseases that continue to progress within the first 4 weeks of enrollment
* Unwilling to avoid using contact lenses during research treatment
* History of immunodeficiency, includingHuman Immunodeficiency Virus（HIV） positivity or other acquired or congenital immunodeficiency diseases
* There are poorly controlled autoimmune diseases that require the use of immunosuppressants or systemic hormone therapy to achieve immunity Subjects who inhibit the purpose and need to continue using it within 7 days before the first administration
* Individuals with epilepsy who require treatment
* Poor control of diabetes
* Tumor related symptoms and treatment:
1. Received chemotherapy, immunotherapy, small molecule targeted drugs, etc. within 3 weeks before the first administration;
2. Traditional Chinese patent medicines and simple preparations with anti-tumor indications specified in the National Medical Products Administration (NMPA )approved drug directions within 1 week before the first drug use;
3. Imaging (Computed Tomography or Magnetic Resonance Imaging) shows that the tumor has invaded important blood vessels, or the researcher has determined that the tumor is highly likely to invade important blood vessels and cause fatal massive bleeding during subsequent studies;
4. Uncontrolled pleural effusion, pericardial effusion, or moderate to severe ascites that still require repeated drainage;
5. Known to have spinal cord compression, meningeal metastasis/malignant meningitis, accompanied by symptoms of brain metastasis, or symptoms/imaging control time less than 4 weeks. Within 2 weeks before the start of treatment, steroid therapy or dehydration agents are still required;
6. For non-small cell lung cancer subjects known to have meaningful gene mutations such as epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) fusion, ROS Proto-Oncogene 1, Receptor Tyrosine Kinase (ROS) fusion, etc., they should have received corresponding targeted therapy;
7. Subjects with known human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction cancer and breast cancer should have received corresponding anti HER2 treatment;
* Known to be allergic to research drug excipient components
* Previously received targeted FGFR2b monoclonal antibod therapy
* Previously received chemotherapy drugs used in the protocol (limited to subjects receiving combination therapy during the dose escalation phase only)
* Individuals who have participated in and used other anti-tumor clinical trial drugs within 4 weeks prior to their first medication.
* According to the judgment of the researchers, there are situations that seriously endanger the safety of the subjects or affect their ability to complete the study
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cancer Hospital of Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China
ZhuJiang Hospital of Southern Medical University
Guangzhou, Guangdong, China
The Henan Cancer Hospital
Zhengzhou, Henan, China
Hunan Provincial People's Hospital (The First Affiliated Hospital of Hunan Normal University)
Changsha, Hunan, China
Zhongshan Hospital Fudan University
Shanghai, Shanghai Municipality, China
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TQB2210-I-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.